[A preliminary study of low dosage zuclopenthixol depot in Alzheimer's disease].
Persistent psychomotor agitation and psychotic ideation in patients with Alzheimer's disease are normally treated orally with antipsychotic drugs and are occasionally treated with other drugs. Neuroleptics administered intramuscularly at very low doses are an alternative, especially when the patient rejects medicine as a results of his or her anosognosia or of paranoid manifestations. We present the results we obtained after observing the effects of depot zuclopenthixol in six patients with probable Alzheimer's disease (based upon NINCDS-ADRDA criteria). Psychic abnormalities were assessed as per the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms (SANS). Possible extrapyramidal side effects were evaluated by means of the Abnormal Involuntary Movement Scale (AIMS). Initially 60 mg (0.3 ml) were administered intramuscularly and successive doses could be modified by +/-20 mg (0.1 ml) according to results seen on the various scales. During the first six weeks of treatment progressive improvement was noted on all three psychic functions scales in all patients. Between the sixth and twelfth weeks improvement continued although without significant change. The AIMS did not show significant changes in the twelve weeks of follow-up. We consider depot zuclopenthixol at low doses as efficacious in treating persistent psychomotor agitation and/or psychotic manifestations of Alzheimer's disease. No undesired side effects were observed in our group after a twelve week follow-up.
Robles
A
A
Servicio de Neurologia, Hospital General de Galicia, Santiago de Compostela.
Rodríguez Navarrete
F J
FJ
Taboada
O
O
Docasar
L
L
Páramo
M
M
Noya
M
M
D000368:Aged; D000544:Alzheimer Disease / Q000150:complications*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003006:Clopenthixol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D011595:Psychomotor Agitation / Q000188:drug therapy* / Q000209:etiology*
D014150:Antipsychotic Agents; C029674:clopenthixol decanoate; D003006:Clopenthixol
Zuclopentixol depot a baja dosis en la enfermedad de Alzheimer. Estudio preliminar.